Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab in Gynecologic Cancers of Mullerian Origin
NCT02728830Phase 1Completed
- Start
- Jun 2016
- Primary completion
- Jan 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pembrolizumab in epithelial ovarian cancer (EOC), endometrial cancer (EC), fallopian tube cancer (PFTC) and 1 more. Primary endpoint: Change in Tumor Immune Infiltrates as Measured by PD-L1 Modified H-Score. Started Jun 2016; status: completed.
02
Drugs
03
Conditions
epithelial ovarian cancer (EOC)endometrial cancer (EC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT02728830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02728830.